Biotech Values

[DewDiligence]

IDIX – The IDX184 phase-1/2 monotherapy trial in treatment-naïve HCV patients has started; it will test 10 patients (8 on drug, 2 on placebo) in each of four cohorts (single doses of 25, 50, 75, and 100mg):

http://clinicaltrials.gov/ct2/show/NCT00807001

This study is a prerequisite for a phase-2a study of IDX184 with peg-ifn and ribavirin, which is expected to begin during 1Q09.